Nóbrega Leandro, Zanon Jeferson Rodrigo, Andrade Carlos E Eduardo Mattos da Cunha, Schmidt Ronaldo Luis, Dos Santos Marcelo Henrique, Dos Reis Ricardo
Department of Gynecologic Oncology, Barretos Cancer Hospital, Barretos, Brazil
Department of Palliative Care and Nephrology, Cancer Hospital of Jales - Barretos Cancer Hospital, Barretos, Brazil.
Int J Gynecol Cancer. 2022 Sep 6;32(9):1123-1128. doi: 10.1136/ijgc-2022-003679.
Obstructive uropathy is present in almost 50% of patients with advanced cervical cancer and is associated with worse outcomes.
To estimate the prognostic role of hydronephrosis and the impact of ureteral obstruction resolution in patients with locally advanced cervical cancer undergoing treatment.
A retrospective cohort study was conducted of patients with International Federation of Gynecology and Obstetrics 2018 stage IIIB to IVA treated in a tertiary oncologic referral center in Brazil between January 2009 and June 2018. Three different groups were evaluated: (I) without hydronephrosis, (II) with hydronephrosis and urinary diversion, and (III) with hydronephrosis but no urinary diversion. Kaplan-Meier curves and log-rank tests estimated overall survival and progression-free survival based on the presence of hydronephrosis and urinary diversion. Clinicopathological variables were evaluated using univariate and multivariate Cox proportional hazard regression model for overall survival and progression-free survival.
A total of 151 patients were evaluated: group I - 62 (41.1%); II - 44 (29.1%), and III - 45 (29.8%). Stage, histological type or grade, tumor size, parametrial or lymph node involvement were not statistically different between groups. Group I had more favorable overall survival than groups II (p<0.003) and III (p<0.02); however, no difference was noted between groups II and III. Progression-free survival was similar between groups (log-rank test p=0.95). Univariate analysis revealed hydronephrosis (p=0.002) and concurrent chemoradiotherapy (p<0.001) as a prognostic factor for worse overall survival; while tumor size (p=0.023), pelvic lymphadenopathy (p=0.015), and histological type (p=0.03) were associated with worse progression-free survival. On multivariate analysis, hydronephrosis remained as an independently associated factor with worse overall survival (HR=2.06; 95% CI 1.12 to 3.79, p=0.02).
Patients with locally advanced cervical cancer with hydronephrosis had lower overall survival even after controlling for potential confounding factors, but no difference in progression-free survival. Urinary diversion showed no impact on overall survival or progression-free survival.
几乎50%的晚期宫颈癌患者存在梗阻性尿路病,且其与更差的预后相关。
评估肾积水的预后作用以及输尿管梗阻缓解对接受治疗的局部晚期宫颈癌患者的影响。
对2009年1月至2018年6月在巴西一家三级肿瘤转诊中心接受治疗的国际妇产科联盟2018年IIIB至IVA期患者进行一项回顾性队列研究。评估了三个不同的组:(I)无肾积水,(II)有肾积水且行尿流改道,(III)有肾积水但未行尿流改道。Kaplan-Meier曲线和对数秩检验根据肾积水和尿流改道情况估计总生存期和无进展生存期。使用单因素和多因素Cox比例风险回归模型评估临床病理变量对总生存期和无进展生存期的影响。
共评估了151例患者:I组62例(41.1%);II组44例(29.1%),III组45例(29.8%)。各组之间的分期、组织学类型或分级、肿瘤大小、宫旁或淋巴结受累情况无统计学差异。I组的总生存期比II组(p<0.003)和III组(p<0.02)更有利;然而,II组和III组之间未发现差异。各组之间的无进展生存期相似(对数秩检验p=0.95)。单因素分析显示肾积水(p=0.002)和同步放化疗(p<0.001)是总生存期较差的预后因素;而肿瘤大小(p=0.023)、盆腔淋巴结病(p=0.015)和组织学类型(p=0.03)与无进展生存期较差相关。多因素分析显示,肾积水仍然是与总生存期较差独立相关的因素(HR=2.06;95%CI 1.12至3.79,p=0.02)。
即使在控制了潜在混杂因素后,局部晚期宫颈癌合并肾积水的患者总生存期较低,但无进展生存期无差异。尿流改道对总生存期或无进展生存期无影响。